ALKERMES $46 MIL. LIMITED PARTNERSHIP WILL FUND RMP RESEARCH
ALKERMES $46 MIL. LIMITED PARTNERSHIP WILL FUND RMP RESEARCH, Cambridge, Mass.-based Alkermes said April 11. The partnership, named Alkermes Clinical Partners, "was formed to fund the clinical development of receptor mediated permeabilizers (RMPs)," Alkermes said. The offering closed April 10. The offering was sold to a number of "high net worth individuals," Alkermes said. The terms of the partnership stipulate that Alkermes may make a tender offer to buy it out under certain conditions after the technology is licensed. "In connection with the offering, Alkermes issued warrants to purchase up to 2,948,600 shares of Alkermes common stock," the company said. The $46 mil. financing is the third and largest equity infusion for the neuroscience R&D start-up in the last nine months. Alkermes has raised over $100 mil. in public and private financing since last July. The company raised about $20 mil. with its initial public offering in July ("The Pink Sheet" May 27, 1991, T&G-13) and then raised another $40 mil. in October via a secondary offering. Alkermes was founded in 1987. Alkermes' RMPs are designed to help therapeutics reach the brain by temporarily increasing the permeability of the blood brain barrier. Alkermes Clinical Partners' lead compound, RMP-7, entered Phase I trials in healthy subjects this year. RMP-7 will enter Phase II trials as an adjunct to treatment for opportunitistic infections in AIDS patients by the end of the year, Alkermes said. The company expects trials with RMP-7 in brain cancer to begin in 1993.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth